Literature DB >> 19478548

Cytotoxic effects of 2-methoxyestradiol in the hepatocellular carcinoma cell line HepG2.

Reem N Abou El Naga1, Ebtehal El-Demerdash, Samar S Youssef, Ashraf B Abdel-Naim, Mahmoud El-Merzabani.   

Abstract

AIM: The study was designed to examine the potential cytotoxicity of 2-methoxyestradiol (2ME2), a natural 17beta-estradiol metabolite, in hepatocellular carcinoma and the possible underlying mechanisms for this cytotoxicity.
METHODS: The cell line HepG2 was treated with different concentrations of 2ME2 for 48 and 72 h.
RESULTS: Using the sulforhodamine B assay, HepG2 was sensitive to the cytotoxic effect of 2ME2. 2ME2 induced cell arrest at the G(2)/M phase and a significant high percentage of apoptotic cells compared to the control group. Also, 2ME2 induced a significant increase in caspase 9 enzymatic activity after 48 and 72 h of treatment compared with control values. The DNA laddering was observed only in cells treated for 72 h. Furthermore, 2ME2 induced a significant decrease in the expression levels of vascular endothelial growth factor (VEGF) gene compared to the control values.
CONCLUSION: 2ME2 exerts cytotoxic activity in the HepG2 cell line by preferential cell blocking at the G(2)/M phase as well as induction of apoptosis as evidenced by increased caspase 9 enzymatic activity and observed DNA laddering in 2ME2-treated HepG2 cells. In addition, a reduction in hypervascularity is an important postulated mechanism as indicated by the significant reduction in the expression of VGEF, one of the most important angiogenic factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478548     DOI: 10.1159/000221062

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

Review 1.  Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges.

Authors:  Svetlana Verenich; Phillip M Gerk
Journal:  Mol Pharm       Date:  2010-10-21       Impact factor: 4.939

2.  Novel combination of 2-methoxyestradiol and cyclophosphamide enhances the antineoplastic and pro-apoptotic effects on S-180 ascitic tumour cells.

Authors:  Srabantika Mallick; Atish Barua; Goutam Paul; Samarendra Nath Banerjee
Journal:  J Cell Commun Signal       Date:  2017-08-10       Impact factor: 5.782

3.  Estrogen Metabolite 2-Methoxyestradiol Attenuates Blood Pressure in Hypertensive Rats by Downregulating Angiotensin Type 1 Receptor.

Authors:  Yong Zhang; Benard O Ogola; Laxmi Iyer; Vardan T Karamyan; Thomas Thekkumkara
Journal:  Front Physiol       Date:  2022-05-02       Impact factor: 4.755

4.  Evaluation of 2-methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma.

Authors:  Igor Hrgovic; Johannes Kleemann; Monika Doll; Carmen Loquai; Florian Weid; Frank Louwen; Nadja Zoeller; Stefan Kippenberger; Roland Kaufmann; Markus Meissner
Journal:  Mol Clin Oncol       Date:  2021-05-23

Review 5.  Evolving role of Sorafenib in the management of hepatocellular carcinoma.

Authors:  Ioannis A Ziogas; Georgios Tsoulfas
Journal:  World J Clin Oncol       Date:  2017-06-10

6.  Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.

Authors:  Jianwai Ren; George G Chen; Yi Liu; Xianwei Su; Baoguang Hu; Billy C S Leung; Y Wang; Rocky L K Ho; Shengli Yang; Gang Lu; C G Lee; Paul B S Lai
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.